Patent ID: 11896639
Assignee: YALE UNIVERSITY
Field: Pharmaceuticals (Chemistry)
Classification: CPC A | IPC A

Claim 4:
5. The method of claim 1, wherein the signaling transduction activity response assay omprises measuring the signal transduction activity response against one or more signaling pathways selected from the group consisting of: Tumor necrosis factor alpha-Nuclear factor kappa-light-chain-enhancer of activated B cells (TNFa-NFkB), Toll like receptor 2-Nuclear factor kappa-light-chain-enhancer of activated B cells (TLR2-NFkB), Toll like receptor 4-Nuclear factor kappa-light-chain-enhancer of activated B cells (TLR4-NFkB), Interleukin 6-Signal transducer and activator of transcription 3 (IL6-stat3), Interferon gamma-Signal transducer and activator of transcription 1/1(IFNg-stat1/1), Interferon alpha-Signal transducer and activator of transcription 1/1(IFNa-statl/2), Dexamethasone-Glucocorticoid receptor (DEX-GR), Cyclooxygenase-2 (COX-2), Inducible nitric oxide synthase (iNOS), Nuclear factor-erythroid factor 2-related factor 2(NRF2), Transforming growth factor beta-Mothers against decapentaplegic homolog 3(TGFb-Smad2/3), Tissue plasminogen activator-Activator protein 1(TPA-AP1), cAMP response element-binding protein (CREB), Wingless/Integrated 3a-Lymphoid enhancer factor/beta catenin (wnt3a-Lef/b-cat), Vitamin D3-vitamin D receptor (VD3-VDR), Estrogen receptors alpha (ER-alpha), Estrogen receptors beta (ER-beta), Dihydrotestosterone-Androgen receptor (DHT-AR), and Aldosterone-Mineralocorticoid receptor (aldosterone-MR).